Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma

WEDNESDAY, Feb. 17, 2021 -- For adults with papillary renal cell carcinoma (PRCC), the dual vascular endothelial growth factor (VEGF)-MET (hepatocyte growth factor receptor) inhibitor cabozantinib improves progression-free survival (PFS), according...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news